Abstract
Stroke is the third most common cause of death, particularly of the elderly. Despite considerable advances in knowledge about the mechanisms of cell death after stroke, a treatment for stroke remains exclusive. For a long time, estrogen was thought of only as a “sex hormone”. Studies have documented that estrogen plays an important role in regulating behavioral and physiological events beyond the reproductive system. Most animal studies have shown that estrogens exert neuroprotective and neurogenesis effects in vivo and in vitro after ischemic stroke. However, clinical and epidemiological evidence shows that estrogen increases the risk of coronary heart disease, stroke, and breast cancer. The discrepancy between animal studies and clinical data emphasizes the importance of performing further investigations using appropriate animal models, and gaining a deeper understanding of the mechanisms of estrogen-mediated neuroprotection and neurogenesis. This review focuses on recent advances in estrogen-mediated neuroprotection and neurogenesis after ischemic stroke, highlighting its potential molecular and cellular mechanisms
Keywords: Estrogen, ischemia, stroke, neuroprotection, neurogenesis, receptor, Ers, inflammation, oxidative stress, excitotoxicity
Current Drug Targets
Title: Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Volume: 13 Issue: 2
Author(s): Bei Shao, Yifan Cheng and Kunlin Jin
Affiliation:
Keywords: Estrogen, ischemia, stroke, neuroprotection, neurogenesis, receptor, Ers, inflammation, oxidative stress, excitotoxicity
Abstract: Stroke is the third most common cause of death, particularly of the elderly. Despite considerable advances in knowledge about the mechanisms of cell death after stroke, a treatment for stroke remains exclusive. For a long time, estrogen was thought of only as a “sex hormone”. Studies have documented that estrogen plays an important role in regulating behavioral and physiological events beyond the reproductive system. Most animal studies have shown that estrogens exert neuroprotective and neurogenesis effects in vivo and in vitro after ischemic stroke. However, clinical and epidemiological evidence shows that estrogen increases the risk of coronary heart disease, stroke, and breast cancer. The discrepancy between animal studies and clinical data emphasizes the importance of performing further investigations using appropriate animal models, and gaining a deeper understanding of the mechanisms of estrogen-mediated neuroprotection and neurogenesis. This review focuses on recent advances in estrogen-mediated neuroprotection and neurogenesis after ischemic stroke, highlighting its potential molecular and cellular mechanisms
Export Options
About this article
Cite this article as:
Shao Bei, Cheng Yifan and Jin Kunlin, Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke, Current Drug Targets 2012; 13 (2) . https://dx.doi.org/10.2174/138945012799201702
DOI https://dx.doi.org/10.2174/138945012799201702 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets Tea and Health: Studies in Humans
Current Pharmaceutical Design Omega-3 Fatty Acids and the Expression of Membrane Proteins: Emphasis on Molecules of Immunologic Importance.
Current Organic Chemistry Patent Selections
Recent Patents on Biotechnology Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets Bioactive Compounds for Effective Management of Drug-Resistant Tuberculosis
Current Bioactive Compounds Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease
Current Pharmaceutical Design Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders How to Measure Exercise Performance
Current Respiratory Medicine Reviews New Insights into Vitamin D and Autophagy in Inflammatory Bowel Diseases
Current Medicinal Chemistry Collagen Receptor Integrins: Rising to the Challenge
Current Drug Targets Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Relationship Between Inflammation, Insulin Resistance and Type 2 Diabetes: Cause or Effect?
Current Diabetes Reviews Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis